Immatics Presents First Cohort Data on the ACTolog® Personalized Multi-Target Cell Therapy Trial Demonstrating Safety and T-cell Persistence in Treated Cancer Patients

(PresseBox) ( San Francisco, )
Immatics Biotechnologies GmbH, a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting cancer immunotherapies, announced today a comprehensive data set having completed the first cohort of the ACTolog® Personalized Multi-Target T-cell Therapy Trial (Study code: IMA101-101, NCT02876510) at the AACR Special Conference on Immune Cell Therapies for Cancer.

ACTolog® is an adoptive cell therapy (ACT) product using the patient’s own (autologous), non-genetically engineered (endogenous) T cells. “To our knowledge, this is the first time that patients are being treated with multiple defined cell therapy products directed against multiple specific tumor targets. For each of the T-cell products the actual expression of the targets is confirmed in a fresh tumor biopsy taken prior to product manufacturing. ACTolog® is taking personalized cell therapy to the next level – aiming to provide effective treatments for patients with advanced solid cancers”, states Dr. Harpreet Singh, CEO of Immatics.

The ACTolog® approach has been pioneered by Prof. Cassian Yee at MD Anderson and expanded by Immatics to include multiple proprietary cancer targets discovered by Immatics’ XPRESIDENT® platform. The trial is led by Principal Investigator Prof. Apostolia M. Tsimberidou and Co-Principal Investigator Prof. Borje S. Andersson with collaboration from other MD Anderson colleagues.

The data set will be provided in three oral presentations and two poster presentations by Prof. Tsimberidou, Dr. Nowak and Dr. Singh– for details see below.

The main conclusions from the currently available data set (N=9 patients, immune data for N=7 patients) are:


All patients entered the trial with progressive disease, having failed the previous line of therapy. Median duration of disease of the patients was 4 years (range 2-18 years) with a median of 6 previous rounds of treatment (range 3-12). Patients received a median of 2 target-specific ACTolog® products (range 1-3).
ACTolog® IMA101 is well tolerated. The most common adverse events, as expected, were cytopenias associated with the lymphodepleting regimen and Grade 1-2 cytokine release syndrome.
High frequencies and persistence of target-specific CD8+ T cells of up to 50% of peripheral CD8+ T cells (measured ex vivo) were observed within the blood of patients up to 12 weeks after adoptive transfer.
Comprehensive cellular immunomonitoring indicates a favorable phenotype of infused T cells.
All treated patients had stable disease by RECIST and irRECIST at 6 weeks and are alive to date after a median follow-up of 8 months.


 The trial is part of a series of research programs and clinical trials conducted in a strategic alliance between Immatics and MD Anderson. The ACTolog® T-cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with The University of Texas Health Science Center in Houston (UTHealth).

About ACTolog® T-cell Therapy


The ACTolog® concept is one of the first actively personalized, multi-targeted Adoptive Cell Therapies (ACT). It is based on the principle of endogenous T-cell therapy pioneered by Professor Cassian Yee, M.D. Unlike tumor-infiltrating lymphocytes, ACTolog® T-cell products are generated from peripheral blood cells with defined target selectivity. Utilizing its proprietary antigen discovery platform XPRESIDENT®, Immatics has created a warehouse of eight cancer targets. From this warehouse, the most suitable targets for each patient’s tumor are identified by analyzing the tumor biomarkers. Up to four personalized T-cell products are then manufactured for each patient by activation and enrichment of the patient’s specific endogenous T cells in vitro. Billions of such activated and specific T cells are then re-infused into the cancer patient to attack the tumor. The ACTolog® T-cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with the University of Texas Health Science Center in Houston (UTHealth).
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to service@pressebox.de.